<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;ACR Appropriateness Criteria&amp;reg; early-stage non&amp;ndash;small-cell lung cancer.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Videtic GM, Rosenzweig KE, Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Loo BW Jr, Movsas B, Stinchcombe TE, Willers H, Expert Panel on Radiation OncologyâLung. ACR Appropriateness CriteriaÂ® early-stage non-small-cell lung cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2013. 14 p.  [75 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;ACR Appropriateness Criteria&amp;reg;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Clinical Condition:&lt;/span&gt; Early-Stage Non&amp;ndash;Small-Cell Lung Cancer&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 1:&lt;/span&gt; 70-year-old man, former smoker with 2-cm peripheral right upper lobe (RUL) adenocarcinoma; PET shows hypermetabolic uptake at RUL lesion but is otherwise negative; mediastinoscopy negative; FEV1 60% predicted; Karnofsky Performance Scale (KPS) 90.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 1: 70-year-old man, former smoker with 2-cm peripheral right upper lobe (RUL) adenocarcinoma; PET shows hypermetabolic uptake at RUL lesion but is otherwise negative; mediastinoscopy negative; FEV1 60% predicted; Karnofsky Performance Scale (KPS) 90&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;30%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;20%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Major Pulmonary Resection&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Lobectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Pneumonectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;VATS (with major or sublobar resection)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Limited resection (wedge/segmentectomy)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Systemic Therapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant chemotherapy&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant biologics&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Chemotherapy only&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Radiotherapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive external beam radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive hypofractionated radiotherapy (2.5&amp;ndash;6 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant fractionated radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;SBRT&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Surgery is the gold standard treatment. SBRT clinical trials are underway. When thinking of this procedure, consider comorbidities and patient factors.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;RFA&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Observation&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale:&lt;/span&gt; 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 2:&lt;/span&gt; 68-year-old woman with 4.2-cm left upper lobe (LUL) adenocarcinoma on CT-guided biopsy; PET shows hypermetabolic uptake at lingular lesion but is otherwise negative; FEV1 70% predicted; KPS 70; concurrent rheumatoid arthritis under control.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 2: 68-year-old woman with 4.2-cm left upper lobe (LUL) adenocarcinoma on CT-guided biopsy; PET shows hypermetabolic uptake at lingular lesion but is otherwise negative; FEV1 70% predicted; KPS 70; concurrent rheumatoid arthritis under control&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;30%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;20%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Major Pulmonary Resection&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Lobectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Pneumonectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;VATS (with major or sublobar resection)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;7&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Limited resection (wedge/segmentectomy)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Systemic Therapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant chemotherapy&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant biologics&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Chemotherapy only&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Radiotherapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive external beam radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive hypofractionated radiotherapy (2.5&amp;ndash;6 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant fractionated radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;SBRT&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;6&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;RFA&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Observation&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale:&lt;/span&gt; 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 3:&lt;/span&gt; 73-year-old woman with COPD, on stable 2 L oxygen by nasal prongs, new 1-cm LUL lesion on chest radiograph after upper respiratory tract infection treated successfully with antibiotics; PET shows hypermetabolic uptake at LUL lesion with SUV 5 but is otherwise negative; bronchoscopy washings positive for adenocarcinoma; FEV1 40%; DLCO 45% predicted; KPS 70.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 3: 73-year-old woman with COPD, on stable 2 L oxygen by nasal prongs, new 1-cm LUL lesion on chest radiograph after upper respiratory tract infection treated successfully with antibiotics; PET shows hypermetabolic uptake at LUL lesion with SUV 5 but is otherwise negative; bronchoscopy washings positive for adenocarcinoma; FEV1 40%; DLCO 45% predicted; KPS 70&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;30%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;20%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Major Pulmonary Resection&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Lobectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Pneumonectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;VATS (with major or sublobar resection)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Limited resection (wedge/segmentectomy)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Systemic Therapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant chemotherapy&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant biologics&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Chemotherapy only&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Radiotherapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive external beam radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive hypofractionated radiotherapy (2.5&amp;ndash;6 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;6&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant fractionated radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;SBRT&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;RFA&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Observation&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale:&lt;/span&gt; 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 4:&lt;/span&gt; 83-year-old man with 3-cm right infrahilar adenocarcinoma; PET shows hypermetabolic uptake at right lesion with SUV 10 but is otherwise negative; FEV1 40% predicted; KPS 70.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 4: 83-year-old man with 3-cm right infrahilar adenocarcinoma; PET shows hypermetabolic uptake at right lesion with SUV 10 but is otherwise negative; FEV1 40% predicted; KPS 70&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;30%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;20%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Major Pulmonary Resection&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Lobectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Pneumonectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;VATS (with major or sublobar resection)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Limited resection (wedge/segmentectomy)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Systemic Therapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant chemotherapy&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant biologics&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Chemotherapy only&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Radiotherapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive external beam radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive hypofractionated radiotherapy (2.5&amp;ndash;6 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;6&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant fractionated radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;SBRT&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;RFA&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Observation&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale:&lt;/span&gt; 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 5:&lt;/span&gt; 70-year-old man with new 2-cm RUL PET-avid lesion with SUV 5 but otherwise negative. The pulmonologist's assessment is that the lesion is too peripheral to sample and that a CT biopsy would be unsafe, which was confirmed by an experienced interventional radiologist. FEV1 50%/DLCO 50% predicted; KPS 70, wears supplemental O&lt;sub&gt;2&lt;/sub&gt; at night.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 5: 70-year-old man with new 2-cm RUL PET-avid lesion with SUV 5 but otherwise negative. The pulmonologist's assessment is that the lesion is too peripheral to sample and that a CT biopsy would be unsafe, which was confirmed by an experienced interventional radiologist&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;30%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;20%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;bottom&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Major Pulmonary Resection&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Lobectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Pneumonectomy + nodal dissection/sampling&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;VATS (with major or sublobar resection)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Limited resection (wedge/segmentectomy)&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Systemic Therapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant chemotherapy&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant biologics&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Chemotherapy only&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Radiotherapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive external beam radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Definitive hypofractionated radiotherapy (2.5&amp;ndash;6 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Adjuvant fractionated radiotherapy (1.8&amp;ndash;2 Gy/fraction)&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;SBRT&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;7&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;RFA&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Observation&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale:&lt;/span&gt; 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Summary of Literature Review&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Introduction/Background&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Lung cancer is the most common malignancy worldwide, with more than one million cases diagnosed yearly. In the United States, 2012 cancer statistics estimated 226,160 new cases and 160,340 deaths due to lung cancer, making it the leading cause of cancer mortality in both men and women. Almost 85% of lung cancers are non&amp;ndash;small-cell (NSCLC) in histology. Approximately 15% to 20% of NSCLC patients present with localized, node-negative disease (&quot;early stage&quot;). Recently, the International Association for the Study of Lung Cancer issued a new staging manual that included changes to the lung cancer staging system. These changes included greater emphasis on primary tumor size as a prognostic factor, resulting in further stratification of T1 and T2 tumors and reclassification of tumors larger than 7 cm as T3. Additionally, although tumors &amp;lt;5 cm remained stage I, tumors between 5 and 7 cm are now grouped into stage IIA. For the purposes of this review, however, early-stage tumors will follow the definitions within the American Joint Committee on Cancer (AJCC) staging manual, sixth edition, since relevant research and current practice have been largely based on those criteria. For patients deemed fit for an operation who have a clinical diagnosis of stage I NSCLC, surgical intervention has historically been the gold standard.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Assessment of Patient Operability&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Baseline pulmonary function will help determine a patient's suitability for resection. The potential decline in lung function will vary with the extent of the resection; pneumonectomy causes the greatest decline in pulmonary function values (including forced expiratory volume in one second [FEV1], forced vital capacity, and maximum oxygen consumption), whereas lobectomy causes less decline than pneumonectomy. FEV1 declines less with a segmentectomy than with a lobectomy. Pulmonary function may recover in 3 to 6 months after a lobectomy and from 6 months to indefinitely to recover after a pneumonectomy. Current evidence suggests that surgery should not be withheld on the basis of age alone in patients who otherwise have acceptable pulmonary function testing. Two sets of guidelines for preoperative evaluation of the lung resection candidate, one from the British Thoracic Society and Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party and the second by the American College of Chest Physicians, have been published and should be referred to for the algorithms provided to assess the lung cancer patient. Most objective assessment criteria in these guidelines are similar and include the premise that individuals with lung cancer should be assessed by a multidisciplinary team to determine their suitability for lung resection. Surgical outcomes, in fact, appear related to expertise, and patients are best assessed by a thoracic surgical oncologist who devotes a significant portion of his/her practice to treating lung cancer. Lastly, patients are best managed in health care centers with expertise in major pulmonary resection because surgical experience and hospital volume to significantly impact morbidity and mortality.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of the Medically Operable Lung Cancer&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Standard Approach&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with a clinical diagnosis of stage I NSCLC and who are deemed appropriate for resection, surgical resection, usually via lobectomy, with mediastinal lymph node sampling or dissection remains the standard of care and is based essentially on historical experience and empirical data as reported in the literature. Lobectomy is generally the preferred treatment as warranted by tumor location, with pneumonectomy generally reserved for central tumors in which sleeve lobectomy would not allow for adequate margins. Surgical mortality is low in most modern reports. For patients undergoing comprehensive preoperative assessment, the risk of surgical mortality should be &amp;le;4% for lobectomy and &amp;le;9% for pneumonectomy. In patients with stage I NSCLC who are considered appropriate candidates for thoracoscopic anatomic lung resection (lobectomy or segmentectomy), there is increasing use of video-assisted thoracoscopic surgery (VATS) by surgeons experienced in these techniques, and this approach may be an acceptable alternative to open thoracotomy in select cases. A systemic review and meta-analysis of randomized and nonrandomized patients undergoing VATS for early-stage NSCLC revealed no significant difference between VATS and open lobectomy in the rate of postoperative complications, mortality, or locoregional recurrence but did suggest a lower rate of systemic recurrence (&lt;em&gt;P &lt;/em&gt;= .03) and 5-year mortality rate with VATS (&lt;em&gt;P&lt;/em&gt; = .04) (see Variant 1, above).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients undergoing major resection for stage I NSCLC, intraoperative comprehensive mediastinal lymph node sampling or dissection is generally recommended for accurate pathologic staging. Of interest, a Cochrane-pooled analysis of randomized trials has shown survival is superior in patients undergoing complete mediastinal lymph node dissection compared with those having lymph node sampling. On the other hand the trial ACOSOG Z0030 has analyzed the survival impact after lung resection of lymph node dissection versus lymph node sampling. Preliminary analysis has found no difference in operative mortality based on lymph node procedure. In a recent review of more than 13,000 early-stage lung cancers treated with resection from 1990 to 2000 and classified as pathologic stage I NSCLC by the AJCC staging manual, sixth edition, the 5-year overall survival (OS) rate for stage IA and IB disease was 71% to 77% and 35% to 58%, respectively.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Limited Resection&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients whose cardiopulmonary function precludes major pulmonary resection, alternative surgical strategies have been described. For select patients with chronic obstructive pulmonary disease (emphysema), favorable results for combined lung volume reduction surgery with curative-intent lung cancer resection have been reported. Limited parenchymal resections such as wedge resection and segmentectomy also have been advocated for compromised patients. Cancer and Leukemia Group B (CALGB) 9335, a prospective trial evaluating the feasibility of VATS-based wedge resection in high-risk patients with clinical T1N0M0 NSCLC, found overall high operative failure rates (29%) and also noted the need to convert some study patients (17%) to conventional thoracotomy. Critically, limited resection may not offer equivalent oncologic outcomes compared with major pulmonary resection in high-risk patients. The Lung Cancer Study Group carried out a prospective randomized trial comparing lobectomy with limited resection in 247 patients with peripheral clinical stage IA NSCLC. This study found that locoregional recurrence was tripled (18% versus 6%) in the limited resection group compared with lobectomy, and a statistical trend suggested that OS and disease-specific survival was impaired by limited resection. This study established lobectomy as the standard of care for the medically operable patient with early-stage disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;External Beam Radiotherapy (EBRT) or Brachytherapy after Limited Resection&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Postoperative EBRT has been employed to improve local control after limited resections in high-risk patients with mixed results: some series suggest feasibility and safety, but others note challenges in defining the postoperative target. The use of intraoperative brachytherapy (i.e., the physical placement of radioactive iodine seeds in the surgical bed) in the setting of limited resections has been more frequently used to overcome the higher failure rates associated with limited resections while limiting potential toxicity from EBRT. Some published series report brachytherapy as well tolerated with satisfactory local control rates and limited radiation-associated toxicity. However, others note significant surgical- and brachytherapy-related complications with this combined approach. The American College of Surgeons Oncology Group trial Z4032 recently completed a phase III trial comparing wedge resection with or without brachytherapy for stage I NSCLC patients at a high risk for major pulmonary resection. The results of this study should serve as a benchmark for the efficacy and toxicity of adjuvant brachytherapy after limited resection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adjuvant Radiotherapy (RT) after Standard Surgical Resection&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is no established role for adjuvant RT after standard surgical resection of early-stage disease. In 1998, the Post Operative Radiation Therapy (PORT) trials group completed a large meta-analysis involving data from 9 randomized trials and reported on pooled outcomes from patients treated with or without adjuvant RT after resection for stage I to III NSCLC. This report revealed a 24% reduction in local recurrence but an absolute increase in mortality of 7% at 2 years when using adjuvant radiation, which on subset analysis was restricted to patients with stage I or II NSCLC. In contrast, a randomized single institution trial published in 2002 specifically addressed the role of adjuvant RT in resected stage I NSCLC and found a decrease in local recurrence from 23% to 2% in the patients receiving adjuvant RT to the bronchial stump and hilum, and without an associated survival detriment. This study has not been replicated. Lastly, a subgroup analysis of the ANITA trial, a phase III study of the survival benefit of adjuvant Navelbine&amp;reg; in resected stage I, II, and IIIA NSCLC patients, looked at the impact of PORT administered in a nonrandomized fashion and found no support for the use of PORT in patients with N0 disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adjuvant Chemotherapy after Standard Surgical Resection&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In general, there are no prospective randomized data to support the routine use of adjuvant cisplatin-based chemotherapy for patients with resected stage I NSCLC. Although large, contemporary randomized trials of adjuvant cisplatin-based chemotherapy versus observation in resected stage I-III NSCLC have been published, none of the studies found improvement in OS in the subset of patients with stage I disease. In a meta-analysis of individual patient data from the 4,584 patients enrolled on these 5 trials, although an absolute 5-year OS benefit of 5.4% (hazard ratio [HR] of 0.89, 95% confidence interval [CI], 0.82&amp;ndash;0.96), and a statistically significant interaction between chemotherapy effect and stage for OS survival was observed (&lt;em&gt;P&lt;/em&gt; = .04), for patients with stage IA disease (n=347) the HR favored observation, suggesting a potential detrimental effect to chemotherapy (HR of 1.41, 95% CI, 0.96&amp;ndash;2.09). For patients with stage IB (n=1,371) there was a trend towards a beneficial effect of chemotherapy that did not reach statistical significance (HR of 0.93, 95% CI, 0.78&amp;ndash;1.10). For patients with resected stage II/III disease, a statistically significant benefit for adjuvant cisplatin-based chemotherapy was seen. CALGB 9633 trial randomized patients with resected stage IB NSCLC to 4 cycles of adjuvant carboplatin and paclitaxel or observation. Final results of this study suggested no survival benefit related to the addition of chemotherapy after an interim analysis had suggested a possible early improvement. That said, an unplanned, retrospective subset analysis suggested that patients with &amp;ge;4-cm tumors (n=196) may obtain a small survival benefit with adjuvant carboplatin and paclitaxel, but this finding remains controversial (see Variant 2, above). In Japan, the drug tegafur-uracil (UFT) has been tested in the adjuvant setting in a number of randomized trials. A meta-analysis of 6 trials comparing surgery alone versus surgery followed by adjuvant UFT confirmed the survival benefit of this drug in resected early-stage lung cancer. UFT is not available outside Japan.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of the Medically Inoperable Patients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;About 20% to 30% of patients with potentially resectable but medically inoperable early-stage NSCLC are not offered surgery because of the increased risk from their medical comorbidities, of which impaired pulmonary function is the most common. For compromised patients, observation alone leads to unacceptable outcomes; lung cancer was shown to be cause of death in 53% of 75 stage I medically inoperable patients not receiving definitive therapy in one reported study. Treatment options frequently offered to this population include limited surgical resection (see above) or conventional RT (see below); however, outcomes appear inferior to lobectomy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Conventional Radiotherapy in the Medically Inoperable Patient&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For medically inoperable early-stage NSCLC patients offered EBRT alone using conventional techniques as primary management, lung cancer results have been consistently inferior to the surgical results reported for operable patients. In a review of 18 studies published from 1988 to 2000 on conventional RT for stage I NSCLC, where the median RT dose was 60 Gy in 30 fractions, local recurrence was the most common cause of failure, ranging up to 70%. A similar report on clinical stage I NSCLC treated with RT alone using modern techniques and staging, with a median RT dose of 64 Gy, overall and progression-free survival rates at 5 years were 48% and 28%, respectively. In that study, 49% of patients had local failure as part of their relapse pattern.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Additionally, accelerated conformal radiation therapy has been investigated for early-stage NSCLC. In a CALGB study, the nominal dose of radiation therapy was kept at 70 Gy, while the number of fractions was reduced from 29 to 17, and the dose per fraction was increased from 2.41 Gy to 4.11 Gy. Out of 39 patients treated, local relapse was observed in 3, and the treatment was well tolerated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Stereotactic Body Radiotherapy (SBRT)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;SBRT, also known as stereotactic ablative radiotherapy, involves RT delivery using very high doses per fraction; rapid dose drop-off in the surrounding normal tissues; RT delivery over few sessions; administration only to small (i.e., &amp;lt;5 cm) discrete targets without regional micrometastatic spread (i.e., without nodal involvement); and applicable to organs whose functional structures could support focal ablation of physiologic units without compromising overall functionality (e.g., liver, lung). Over the past decade, a range of publications have now described stereotactic approaches to the management of early-stage lung cancer, with a range of technological approaches and dose regimens ranging from as many as 10 fractions to as few as a single fraction. In summary, results from these retrospective and prospective reports demonstrate a consistent theme: the suggestion of excellent outstanding local control with SBRT for stage I patients with nearly all series reporting 85% to 98.5% control rates. Of interest, there appears to be an SBRT dose-response relationship for lung cancer since local failure rates appear to rise when the treatment dose is less than a certain biological threshold: using radiobiological parameters, SBRT doses are felt to require a biologically equivalent dose of at least equivalent 100 Gy&lt;sub&gt;10&lt;/sub&gt; to achieve similar control rates. With positron emission tomography (PET)-based staging primarily employed in most SBRT series, mediastinal or hilar nodal failures appear to be rare, ranging from 0% to 10%. Distant failure remains the predominant pattern of failure for patients treated with SBRT, at the rate of 15% to 30% of stage I patients treated with SBRT. The Radiation Therapy Oncology Group&amp;reg; (RTOG&amp;reg;) initiated a prospective phase I/II trial (RTOG 0236) in medically inoperable peripherally located early-stage NSCLC measuring &amp;le;5 cm utilizing a regimen of 60 Gy (54 Gy with heterogeneity correction) in 3 fractions over 8 to 14 days. The study went on to enroll 59 patients over a multi-institutional setting and closed in October 2006. Study results have recently been published and were remarkable for a 3-year primary tumor control rate of 97.6%, a local-regional control rate of 87.2%, and a median OS of 48.1 months with no treatment-related deaths reported (see Variant 3, above).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Regarding the concept of heterogeneity correction as noted above for the SBRT total dose (i.e., 60 Gy [54 Gy with heterogeneity correction]), tissue heterogeneity in the vicinity of the lung has implications on the accuracy of the dose distributions. Dose that would have normally been deposited in the tumor is carried away into the surrounding lung tissue, resulting in potential underdosage of the tumor. The literature is replete with articles demonstrating the need for accurate, &quot;heterogeneity-corrected&quot; dose algorithms in lung cancer planning. Consequently, the RTOG has adopted the requirement that algorithms employing heterogeneity corrections be used for treatment planning for both early and locally advanced stage lung cancer. To mitigate inaccuracies with dose calculations, it is strongly recommended that algorithms employing accurate heterogeneity correction techniques be used for lung cancer treatment planning. Pencil-beam-type algorithms should be avoided.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There has consistently been remarkably little toxicity reported with SBRT used in medically inoperable early-stage lung cancer patients, with grade 3 or higher rates typically less than 4%. The major exception to the low rates of SBRT toxicity was reported by researchers following their experience of treating &quot;central&quot; lung tumors, defined as lying within 2 cm of the tracheobronchial tree, in the setting of phase II series using a dose schedule that ultimately provided the basis for RTOG 0236 (60 Gy [54 Gy with heterogeneity correction] in 3 fractions). In that phase II experience, 54% of patients with &quot;central&quot; tumors were free from severe toxicity for 2 years. In contrast, central lesions have routinely been safely treated with slightly lower total doses and dose per fraction (such as 50 Gy in 4&amp;ndash;5 fractions) with similar local control and toxicity as seen in treatment of &quot;peripheral&quot; lesions to higher doses when normal tissue tolerances were respected (see Variant 4, above). In spite of the high baseline prevalence of pulmonary comorbidities in patients treated with lung SBRT, the incidence of symptomatic radiation pneumonitis is very low, ranging from 0% to 5% in reported series. Recent reports have highlighted chest wall pain or rib fracture as an increasingly noted delayed side effect, though symptoms are typically mild to moderate. Chest wall symptoms are reported in 5% to 15% of patients with peripheral lesions and appear to be related to treatment dose, fractionation, and beam arrangement.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Given that lung cancer patients treated with SBRT generally have significant medical comorbidities, approaches to staging and workup are frequently intended to be noninvasive and minimally harmful. Although pathologic confirmation of malignancy by biopsy is the gold standard, this is not readily achievable in some patients due to medical contraindications. For those nonbiopsied patients, treatment is then offered on the basis of a clinical diagnosis of cancer, i.e., based only on radiographic criteria such as serial computed tomography (CT) chest scans showing a growing lesion and an accompanying fluorine-18-2-fluoro-2-deoxy-D-glucose PET scan either demonstrating high (standardized uptake value [SUV] &amp;gt;5) metabolic activity on a single scan, or progression of intermediate activity over serial scans. Nonbiopsied patients treated with SBRT may represent up to 30% of some practices; studies to date suggest reassuringly that such patients have outcomes similar to the biopsy-proven cases (see Variant 5, above). Similarly, mediastinoscopy is rarely carried out in these patients. CT-based, and more recently PET-based, staging has been used to characterize and clinically define the mediastinal lymph nodes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Radiofrequency Ablation (RFA)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;RFA has been described as a treatment option for medically inoperable early-stage lung cancer. RFA involves placing an electrode within the tumor tissue, which will generate heat from radiofrequency energy, leading to tumor destruction and necrosis around the electrode. A number of retrospective series involving varied patient populations have been published on the use of RFA to treat lung malignancies. Complete radiographic responses achieved with RFA are reported in 38% to 93% of tumors. Primary tumor relapse rates after RFA range from 8% to 43%. Two-year cancer-specific survival after RFA ranges from 57% to 93% and overall 3-year survival rates range from 15% to 46%. Smaller tumor size, metastases, and an ablation zone 4 times the tumor diameter may predict complete response. Pneumothorax has been reported in subjects as an adverse event, with some patients requiring catheter or chest tube insertion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American College of Chest Physicians (ACCP) and Society of Thoracic Surgeons (STS) discuss this modality in their 2012 consensus statement on the management of the high-risk lung cancer patient. Per the ACCP/STS report, the reduced primary control seen with RFA makes it a reasonable treatment option only for those high-risk patients with peripheral lesions who are not candidates for SBRT or sublobar resection or have failed prior SBRT. The risks and benefits of RFA in a medically compromised population remain to be defined, and prospective comparisons with potentially less morbid treatments such as SBRT are not yet published.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Summary&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with early-stage lung cancer are best cared for by a multidisciplinary team with expertise in thoracic malignancies. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For medically operable early-stage lung cancer patients, major pulmonary resection and appropriate nodal dissection remain the gold standard for cure of stage I NSCLC. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine use of adjuvant RT and/or chemotherapy for resected stage I lung cancer patients is not recommended, however carefully selected patients with high-risk features may be considered for such treatments. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For patients who present with significant surgical risks or who have significant competing comorbidities, attempting cure must be balanced by minimizing treatment toxicities. Developments in surgery (e.g., limited resection with or without intraoperative brachytherapy); radiation therapy (e.g., SBRT) and interventional radiology (e.g., RFA) offer potential means of achieving this balance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;With excellent local control and minimal side effects, lung SBRT is emerging as standard treatment for medically inoperable stage I NSCLC, particularly for peripherally located lesions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ongoing studies are defining the role of SBRT for high-risk or fully operable early-stage NSCLC and the optimal SBRT dose and fractionation in different clinical situations (such as central lesions). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The role of RFA needs to be further defined. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Abbreviations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;COPD, chronic obstructive pulmonary disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CT, computed tomography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;DLCO, diffusion capacity for carbon monoxide &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;FEV1, forced expiratory volume in one second &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;KPS, Karnofsky Performance Scale &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;LUL, left upper lobe &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PET, positron emission tomography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;RFA, radiofrequency ablation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;RUL, right upper lobe &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;SBRT, stereotactic body radiotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;SUV, standardized uptake value &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;VATS, video-assisted thoracoscopic surgery &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Algorithms were not developed from criteria guidelines.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Early-stage non&amp;ndash;small-cell lung cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Oncology" />
      <FieldValue Value="Pulmonary Medicine" />
      <FieldValue Value="Radiation Oncology" />
      <FieldValue Value="Radiology" />
      <FieldValue Value="Thoracic Surgery" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Health Plans" />
      <FieldValue Value="Hospitals" />
      <FieldValue Value="Managed Care Organizations" />
      <FieldValue Value="Physicians" />
      <FieldValue Value="Utilization Management" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To evaluate the appropriateness of treatment procedures for early-stage non&amp;ndash;small-cell lung cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with early-stage non&amp;ndash;small-cell lung cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Major pulmonary resection&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lobectomy + nodal dissection/sampling &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pneumonectomy + nodal dissection/sampling &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Video-assisted thoracoscopic surgery (VATS) (with major or sublobar resection) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Limited resection (wedge/segmentectomy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Systemic therapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Adjuvant chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adjuvant biologics &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chemotherapy only &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Radiotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Definitive external beam radiotherapy (EBRT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Definitive hypofractionated radiotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adjuvant fractionated radiotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Stereotactic body radiotherapy (SBRT) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Radiofrequency ablation (RFA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observation &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary function values, including forced expiratory volume in one second (FEV1), forced vital capacity, and maximum oxygen consumption &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Survival rates (5-year overall, 2-year cancer-specific, 3-year) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tumor response rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Locoregional and distant recurrence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment-related toxicity &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Literature Search Procedure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Staff will search in PubMed only for peer reviewed medical literature for routine searches. Any article or guideline may be used by the author in the narrative but those materials may have been identified outside of the routine literature search process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Medline literature search is based on keywords provided by the topic author. The two general classes of keywords are those related to the condition (e.g., ankle pain, fever) and those that describe the diagnostic or therapeutic intervention of interest (e.g., mammography, MRI).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search terms and parameters are manipulated to produce the most relevant, current evidence to address the American College of Radiology Appropriateness Criteria (ACR AC) topic being reviewed or developed. Combining the clinical conditions and diagnostic modalities or therapeutic procedures narrows the search to be relevant to the topic. Exploding the term &quot;diagnostic imaging&quot; captures relevant results for diagnostic topics.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following criteria/limits are used in the searches.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Articles that have abstracts available and are concerned with humans. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Restrict the search to the year prior to the last topic update or in some cases the author of the topic may specify which year range to use in the search. For new topics, the year range is restricted to the last 10 years unless the topic author provides other instructions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May restrict the search to Adults only or Pediatrics only. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Articles consisting of only summaries or case reports are often excluded from final results. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The search strategy may be revised to improve the output as needed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The total number of source documents identified as the result of the literature search is not known.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Evidence Key&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 1 - The conclusions of the study are valid and strongly supported by study design, analysis and results.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 2 - The conclusions of the study are likely valid, but study design does not permit certainty.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 3 - The conclusions of the study may be valid but the evidence supporting the conclusions is inconclusive or equivocal.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 4 - The conclusions of the study may not be valid because the evidence may not be reliable given the study design or analysis.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Review of Published Meta-Analyses" />
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The topic author drafts or revises the narrative text summarizing the evidence found in the literature. American College of Radiology (ACR) staff draft an evidence table based on the analysis of the selected literature. These tables rate the strength of the evidence (study quality) for each article included in the narrative text.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The expert panel reviews the narrative text, evidence table, and the supporting literature for each of the topic-variant combinations and assigns an appropriateness rating for each procedure listed in the table. Each individual panel member assigns a rating based on his/her interpretation of the available evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;More information about the evidence table development process can be found in the ACR Appropriateness Criteria&amp;reg; Evidence Table Development document (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus (Delphi)" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Rating Appropriateness&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The appropriateness ratings for each of the procedures included in the Appropriateness Criteria topics are determined using a modified Delphi methodology. A series of surveys are conducted to elicit each panelist's expert interpretation of the evidence, based on the available data, regarding the appropriateness of an imaging or therapeutic procedure for a specific clinical scenario. American College of Radiology (ACR) staff distribute surveys to the panelists along with the evidence table and narrative. Each panelist interprets the available evidence and rates each procedure. The surveys are completed by panelists without consulting other panelists. The appropriateness rating scale is an ordinal scale that uses integers from 1 to 9 grouped into three categories: 1, 2, or 3 are in the category &quot;usually not appropriate&quot;; 4, 5, or 6 are in the category &quot;may be appropriate&quot;; and 7, 8, or 9 are in the category &quot;usually appropriate.&quot; Each panel member assigns one rating for each procedure for a clinical scenario. The ratings assigned by each panel member are presented in a table displaying the frequency distribution of the ratings without identifying which members provided any particular rating.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If consensus is reached, the median rating is assigned as the panel's final recommendation/rating. Consensus is defined as eighty percent (80%) agreement within a rating category. A maximum of three rounds may be conducted to reach consensus. Consensus among the panel members must be achieved to determine the final rating for each procedure.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If consensus is not reached, the panel is convened by conference call. The strengths and weaknesses of each imaging procedure that has not reached consensus are discussed and a final rating is proposed. If the panelists on the call agree, the rating is proposed as the panel's consensus. The document is circulated to all the panelists to make the final determination. If consensus cannot be reached on the call or when the document is circulated, &quot;No consensus&quot; appears in the rating column and the reasons for this decision are added to the comment sections.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This modified Delphi method enables each panelist to express individual interpretations of the evidence and his or her expert opinion without excessive influence from fellow panelists in a simple, standardized and economical process. A more detailed explanation of the complete process can be found in additional methodology documents found on the &lt;a href=&quot;http://www.acr.org/ac&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt; (see also the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations are based on analysis of the current literature and expert panel consensus.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Selection of appropriate radiologic treatment procedures for early-stage non&amp;ndash;small-cell lung cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pneumothorax due to radiofrequency ablation (RFA) has been reported in subjects as an adverse event, with some patients requiring catheter or chest tube insertion. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There has consistently been remarkably little toxicity reported with stereotactic body radiotherapy (SBRT) used in medically inoperable early-stage lung cancer patients, with grade 3 or higher rates typically less than 4%. The major exception to the low rates of SBRT toxicity was reported by researchers following their experience of treating &quot;central&quot; lung tumors, defined as lying within 2 cm of the tracheobronchial tree, in the setting of phase II series using a dose schedule that ultimately provided the basis for RTOG 0236 (60 Gy [54 Gy with heterogeneity correction] in 3 fractions). In that phase II experience, 54% of patients with &quot;central&quot; tumors were free from severe toxicity for 2 years. In contrast, central lesions have routinely been safely treated with slightly lower total doses and dose per fraction (such as 50 Gy in 4&amp;ndash;5 fractions) with similar local control and toxicity as seen in treatment of &quot;peripheral&quot; lesions to higher doses when normal tissue tolerances were respected. In spite of the high baseline prevalence of pulmonary comorbidities in patients treated with lung SBRT, the incidence of symptomatic radiation pneumonitis is very low, ranging from 0% to 5% in reported series. Recent reports have highlighted chest wall pain or rib fracture as an increasingly noted delayed side effect, though symptoms are typically mild to moderate. Chest wall symptoms are reported in 5% to 15% of patients with peripheral lesions and appear to be related to treatment dose, fractionation, and beam arrangement. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Some published series report brachytherapy as well tolerated with satisfactory local control rates and limited radiation-associated toxicity. However, others note significant surgical- and brachytherapy-related complications with this combined approach. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For patients who present with significant surgical risks or who have significant competing comorbidities, attempting cure must be balanced by minimizing treatment toxicities. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Videtic GM, Rosenzweig KE, Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Loo BW Jr, Movsas B, Stinchcombe TE, Willers H, Expert Panel on Radiation OncologyâLung. ACR Appropriateness CriteriaÂ® early-stage non-small-cell lung cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2013. 14 p.  [75 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2013" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="American College of Radiology - Medical Specialty Society" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria&amp;reg;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology&amp;ndash;Lung&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Panel Members&lt;/em&gt;: Gregory M. M. Videtic, MD, CM (&lt;em&gt;Principal Author&lt;/em&gt;); Kenneth E. Rosenzweig, MD (&lt;em&gt;Panel Chair&lt;/em&gt;); Joe Yujiao Chang, MD, PhD (&lt;em&gt;Panel Vice-chair&lt;/em&gt;); Indrin J. Chetty, PhD; Mark E. Ginsburg, MD; Larry L. Kestin, MD; Feng-Ming (Spring) Kong, MD, PhD, MPH; Brian E. Lally, MD; Billy W. Loo, Jr., MD, PhD; Benjamin Movsas, MD; Thomas E. Stinchcombe, MD; Henning Willers, MD&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;https://acsearch.acr.org/docs/3082798/Narrative&quot; title=&quot;ACR Web site&quot;&gt;American College of Radiology (ACR) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Overview. Reston (VA): American College of Radiology; 2013 Nov. 3 p. Available from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/Overview.pdf&quot; title=&quot;ACR Web site&quot;&gt;American College of Radiology (ACR) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Literature search process. Reston (VA): American College of Radiology; 2013 Apr. 1 p. Available from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/LiteratureSearchProcess.pdf&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Evidence table development. Reston (VA): American College of Radiology; 2015 Nov. 5 p. Available from the &lt;a href=&quot;https://www.acr.org/~/media/ACR/Documents/AppCriteria/EvidenceTableDevelopment.pdf?db=web&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg; early-stage non&amp;ndash;small-cell lung cancer. Evidence table. Reston (VA): American College of Radiology; 2013. 38 p. Available from the &lt;a href=&quot;https://acsearch.acr.org/docs/3082798/ET&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on March 12, 2104.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria&amp;reg; may be found on the &lt;a href=&quot;http://www.acr.org/Quality-Safety/Appropriateness-Criteria/TermsConditions&quot; title=&quot;ACR Web site&quot;&gt;Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>